Skip to main content

Table 2 Immune-reactivity score for expression of mTOR, p-mTOR, MMP2, MMP7, MMP9 in the tumor center and at the invasive front of type gastric cancer

From: MMP2 and MMP7 at the invasive front of gastric cancer are not associated with mTOR expression

Targets Intestinal type (n = 86) Diffuse type (n = 42) Overall (N = 128)
  Tumor center Invasive front p-value Tumor center Invasive front p-value Tumor center Invasive front p-value
MMP2 4.10 ± 5.042 7.65 ± 7.782 <0.001* 2.93 ± 3.925 5.40 ± 6.688 0.005* 3.72 ± 4.721 6.91 ± 7.490 <0.001*
MMP7 5.43 ± 8.345 4.48 ± 7.680 0.008* 5.10 ± 8.798 4.50 ± 7.613 (0.128) 5.32 ± 8.463 4.48 ± 7.628 0.002*
MMP9 4.57 ± 7.362 3.97 ± 7.058 (0.227) 5.62 ± 7.821 4.71 ± 6.656 (0.144) 4.91 ± 7.501 4.21 ± 6.912 (0.097)
mTOR 10.95 ± 7.543 9.79 ± 8.778 0.025* 8.67 ± 6.091 9.12 ± 6.463 (0.589) 10.20 ± 7.156 9.57 ± 8.072 (0.127)
p-mTOR 3.42 ± 4.185 2.69 ± 4.610 0.008* 2.13 ± 2.662 2.76 ± 4.667 (0.545) 3.00 ± 3.792 2.71 ± 4.610 0.013*
  1. Comparison between tumor center and invasive front has been done by the Mann–Whitney U-test with significant differences (p < 0.05) marked by an asterisk. Values are given as mean and standard deviation